Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

Axel Le Cesne (1) , Isabelle Ray-Coquard (2) , Binh Nguyen Bui , Antoine Adenis (3) , Maria Rios (4) , François Bertucci (5) , Florence Duffaud (6) , Christine Chevreau (7) , Didier Cupissol (8) , Angela Cioffi , Jean-François Emile (9) , Sylvie Chabaud (10) , David Pérol (11) , Jean-Yves Blay (2)

1 Département de médecine oncologique [Gustave Roussy]
2 Department of Medical Oncology [Lyon]
3 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
4 CAV - Centre Alexis Vautrin
5 CRCM - Centre de Recherche en Cancérologie de Marseille
6 Neuro-Oncologie [Hôpital de la Timone - APHM]
7 Institut Claudius Regaud
8 IRCM - U896 Inserm - UM1 - Institut de recherche en cancérologie de Montpellier
9 Service d'anatomie pathologique [CHU Ambroise-Paré]
10 UBET - Unité de Biostatistique et d'Evaluation des Thérapeutiques
11 Department of Biostatistics

Domains: Life Sciences [q-bio]; Cancer

Axel Le Cesne, Isabelle Ray-Coquard, Binh Nguyen Bui, Antoine Adenis, Maria Rios, et al.. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncology, 2010, 11 (10), pp.942-949. ⟨10.1016/s1470-2045(10)70222-9⟩. ⟨hal-03623804⟩